Geode Capital Management
REVB icon

Geode Capital Management’s Revelation Biosciences REVB Stock Holding History

Geode Capital Management’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.7K Sell
17,192
-26,003
-60% -$28.2K ﹤0.01% 4383
2026
Q1 		$51.8K Buy
43,195
+34,690
+408% +$67.1K ﹤0.01% 4305
2025
Q4 		$27.2K Buy
+8,505
New +$37.2K ﹤0.01% 4342
2025
Q1 		– Sell
-57
Closed -$5.05K – 4502
2024
Q4 		$5.05K Buy
+57
New +$7.59K ﹤0.01% 4460
2024
Q1 		– Sell
-6
Closed -$17.9K – 4632
2023
Q4 		$17.9K Hold
6
– – ﹤0.01% 4531
2023
Q3 		$24.3K Buy
+6
New +$26.5K ﹤0.01% 4585

Other funds holding REVB

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Geode Capital Management's REVB Position: Q2 2026 in Review

Geode Capital Management reduced its Revelation Biosciences (REVB) stake by 60% in Q2 2026, selling an estimated $28.2K and leaving 17,192 shares worth $17.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4383.

Geode Capital Management first reported a position in REVB in Q3 2023 and has held it in 6 quarters since. The position peaked at $51.8K in Q1 2026. 12 funds tracked by Wall St. Rank hold REVB as of Q2 2026.

  • Geode Capital Management held 17,192 shares of Revelation Biosciences worth $17.7K as of Q2 2026.
  • Geode Capital Management sold 26,003 Revelation Biosciences shares in Q2 2026, an estimated $28.2K.
  • Revelation Biosciences made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4383 holding.
  • Geode Capital Management first reported a position in Revelation Biosciences in Q3 2023 and has held it in 6 quarters since.
  • Geode Capital Management's Revelation Biosciences position peaked at $51.8K in Q1 2026.
  • 12 funds tracked by Wall St. Rank held Revelation Biosciences as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.